Study to compare drug availability in bloodstream of two oral formulations of mesalazine in healthy volunteers under fed conditions.

2024-517107-37-00 Protocol CLEU-0524/FED Human pharmacology (Phase I) - Other Ended

Start 20 Dec 2024 · End 21 Feb 2025 · Status Ended · 1 EU/EEA countries · 1 sites · Protocol CLEU-0524/FED

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - Other
Status Ended
Participants planned 60
Countries 1
Sites 1

Chronic idiopathic inflammatory bowel disease

Key facts

Sponsor
Faes Farma S.A.
Participant type
Healthy volunteers
Age range
18-64 years
Gender
Male and Female
Therapeutic area
Diseases [C] - Digestive System Diseases [C06]
Trial duration
20 Dec 2024 → 21 Feb 2025
Decision date (initial)
2024-11-11
Transition trial
No
Low-intervention
No
Rare-disease indication
No
Vulnerable population
No

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Chronic idiopathic inflammatory bowel disease

VersionLevelCodeTermSystem organ class
20.0 PT 10009900 Colitis ulcerative 100000004856

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Faes Farma S.A.

Sponsor organisation
Faes Farma S.A.
Address
Autonomia Etorbidea 10
City
Leioa
Postcode
48940
Country
Spain

Scientific contact point

Organisation
Faes Farma S.A.
Contact name
FAES FARMA Clinical department

Public contact point

Organisation
Faes Farma S.A.
Contact name
FAES FARMA Clinical department

Locations

1 EU/EEA country · 1 investigational sites

By country

CountryMS statusPlanned subjectsSites
Spain Ended 60 1
Rest of world 0

Investigational sites

Spain

1 site · Ended
Hospital Universitario De La Princesa
CLINICAL PHARMACOLOGY, Calle De Diego De Leon 62, 28006, Madrid

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Spain 2024-12-20 2025-02-21 2024-12-26 2025-01-24

Application history

3 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2024-10-04 Spain Acceptable
2024-11-07
2024-11-11
2 NON SUBSTANTIAL MODIFICATION NSM-1 2024-12-16 Spain Acceptable
2024-11-07
2024-12-16
3 SUBSTANTIAL MODIFICATION SM-1 2025-02-03 Spain Acceptable
2025-03-07
2025-03-07